Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -169% Improvement Relative Risk Progression -108% Recovery, ordinal score 7% Recovery, ordinal ≤1 15% Recovery, CT score 24% Colchicine  Sunil Naik et al.  LATE TREATMENT  RCT Is late treatment with colchicine beneficial for COVID-19? RCT 105 patients in India Trial underpowered for serious outcomes c19early.org Sunil Naik et al., Contemporary Clinic.., Jan 2023 Favors colchicine Favors control

Effect of colchicine and aspirin given together in patients with moderate COVID-19

Sunil Naik et al., Contemporary Clinical Trials Communications, doi:10.1016/j.conctc.2023.101070, CTRI/2021/03/032060
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Colchicine for COVID-19
6th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.00000056 from 50 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
RCT 122 hospitalized patients in India, showing improved recovery with colchicine treatment. All patients received aspirin. There was one death and higher progression in the colchicine arm, however 3 patients in the colchicine arm had baseline ordinal scores ≥5, while no patients in the control arm did.
risk of death, 169.4% higher, RR 2.69, p = 1.00, treatment 1 of 62 (1.6%), control 0 of 43 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of progression, 108.1% higher, RR 2.08, p = 0.64, treatment 3 of 62 (4.8%), control 1 of 43 (2.3%).
recovery, 7.3% lower, RR 0.93, p = 0.21, treatment 62, control 43, relative improvement in ordinal score.
risk of no recovery, 15.0% lower, RR 0.85, p = 0.06, treatment 49 of 62 (79.0%), control 40 of 43 (93.0%), NNT 7.1, ordinal score ≤1.
recovery, 24.3% lower, RR 0.76, p = 0.02, treatment 62, control 43, relative improvement in CT score.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sunil Naik et al., 21 Jan 2023, Randomized Controlled Trial, India, peer-reviewed, 3 authors, trial CTRI/2021/03/032060. Contact: rmg.trial21@gmail.com.
This PaperColchicineAll
Effect of colchicine and aspirin given together in patients with moderate COVID-19
K Sunil Naik, Niranjan Andhalkar, Sohal Pendse
Contemporary Clinical Trials Communications, doi:10.1016/j.conctc.2023.101070
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Declaration of interests ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The study has been funded by ROMEG therapeutics LLC n but there is no financial interest to disclose related to trial results and manuscript writing/reviewing/publishing. J o u r n a l P r e -p r o o f
References
Arif, Aggarwal, Salicylic Acid (Aspirin)
Bester, Matshailwe, Pretorius, Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8, Cytokine, doi:10.1016/j.cyto.2018.01.007
Bianconiv, Violi, Fallarino, Pignatelli, Sahebkara et al., Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19?, Drugs, doi:10.1007/s40265-020-01365-1
Cao, Wang, Wen, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2001282
Chandwani, Shuter, Lopinavir/ritonavir in the treatment of HIV-1 infection: a review, Ther Clin Risk Manag, doi:10.2147/tcrm.s3285
Chow, Khanna, Kethireddy, Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission
Cui, Chen, Li, Liu, Wang, Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, J ThrombHaemost, doi:10.1111/jth.14830
Deftereos, Giannopoulos, Vrachatisda, Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.13136
Giannis, Ziogasia, Gianni, Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past, J Clin Virol, doi:10.1016/j.jcv.2020.104362
Godino, Scotti, Maugeri, Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence, International Journal of Cardiology, doi:10.1016/j.ijcard.2020.09.064
Healio, FDA approves ticagrelor-aspirin DAPT to reduce MI, stroke in CAD
J O U R N A L P R E, -p r o o f
J O U R N A L P R E, -p r o o f
Leung, Hui, Kraus, Colchicine--Update on mechanisms of action and therapeutic uses, Semin Arthritis Rheum, doi:10.1016/j.semarthrit.2015.06.013
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial. medRxiv, doi:10.1101/2020.08.06.20169573
Marotta, FDA: Center for Drug Evaluation and Research; Labelling of Aspirin. Food and Drug Administration
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an Old Drug, NewUse. CurrPharmacol Rep, doi:10.1007/s40495-020-00225-
Sriram, Insel Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets, Physiological Reviews
Tardif, Kouz, Waters, Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction, N Engl J Med, doi:10.1056/NEJMoa1912388
Tay, Poh, Rénia, Macary, Ng, The trinity of COVID-19:immunity, inflammation and intervention, Nature Reviews Immunology, doi:10.1038/s41577-020-0311-8
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit